title: Characterization of CD3+ CD4- CD8- (double negative) T cells in patients with systemic lupus erythematosus: production of IL-4.
abstract: Systemic lupus erythematosus (SLE) is a chronic autoimmune rheumatic disease that may affect every organ or system in the body. We have shown previously that the TCR alphabeta+ subpopulation of CD3+ CD4- CD8-, DN T cells is expanded in patients with SLE and that double negative T cells express increased levels of activation markers compared both with healthy people and with patients with rheumatoid arthritis, (RA) as autoimmune controls. The aim of this study was to characterize these cells in terms of their ability to produce IL4, a Th2 cytokine, both spontaneously and after mitogen stimulation. It was found that a higher percentage of TCR alphabeta+ double negative T cells from patients with SLE contained IL4 constitutively than did the same population of cells from healthy people or from those with RA. After mitogen stimulation, there was no significant difference in the amount of IL4 produced by each of the three groups. Further study of patients producing high levels of IL4 (about one third of the patients) indicated that they had a lower percentage of alphabeta+ T cells in the double negative compartment than did patients with fewer IL4 containing cells.
authors.affiliation: Department of Immunology and Molecular Pathology, Royal Free and University College School of Medicine, London, UK.
authors.forename: G S
authors.initials: GS
authors.lastname: Dean
authors.forename: A
authors.initials: A
authors.lastname: Anand
authors.forename: A
authors.initials: A
authors.lastname: Blofeld
authors.forename: D A
authors.initials: DA
authors.lastname: Isenberg
authors.forename: P M
authors.initials: PM
authors.lastname: Lydyard
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000954:Antigens, Surface / Q000032:analysis; D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers / Q000032:analysis; D017252:CD3 Complex / Q000032:analysis*; D015704:CD4 Antigens / Q000032:analysis; D016827:CD8 Antigens / Q000032:analysis; D003176:Complement C3 / Q000378:metabolism; D004247:DNA / Q000276:immunology; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015847:Interleukin-4 / Q000096:biosynthesis*; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis* / Q000188:drug therapy / Q000208:ethnology / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010835:Phytohemagglutinins / Q000494:pharmacology; D044469:Racial Groups; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000032:analysis; D013601:T-Lymphocytes / Q000737:chemistry* / Q000187:drug effects / Q000378:metabolism
chemical_list: D000954:Antigens, Surface; D001323:Autoantibodies; D015415:Biomarkers; D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D003176:Complement C3; D007166:Immunosuppressive Agents; D010835:Phytohemagglutinins; D016693:Receptors, Antigen, T-Cell, alpha-beta; D015847:Interleukin-4; D004247:DNA